COMMUNIQUÉS West-GlobeNewswire

Lifeward Announces Postponement of its Extraordinary General Meeting of Shareholders
27/12/2024
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what [...]
Psyence Biomed Announces Closing of $2.0 Million Private Placement
27/12/2024
NEW YORK, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it has closed its previously announced private placement for the purchase and [...]
Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc.
27/12/2024
Proposed merger would add a differentiated Phase 3 TROP2 Antibody-drug Conjugate (ADC) to the combined company’s pipeline PALO ALTO, Calif., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a [...]
SAFE GROUP - Half-Year Financial Report as of June 30, 2024
27/12/2024
HALF-YEAR FINANCIAL REPORT AS OF JUNE 30, 2024 December 27, 2024, 6.00 p.m. Safe Group announces that it has made available to the public and filed with the Autorité des Marchés Financiers its half-year financial report [...]
SAFE GROUP - Mise à disposition du rapport financier semestriel
27/12/2024
Mise à disposition du rapport financier semestriel Fleurieux-sur-l’Arbresle - France - le 27 décembre 2024 à 18h . Safe Group annonce avoir mis à la disposition du public et déposé auprès de l’Autorité des Marchés [...]
LYNN STOCKWELL ENTERS INTO A RESTRUCTURING SECURITY AGREEMENT (“RSA”) WITH BRIGHT GREEN CORPORATION AND ASSUMES THE ROLE OF EXECUTIVE CHAIR AND CEO.
27/12/2024
GRANTS, NEW MEXICO, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (OTC: BGXX) (“Bright Green” or the “Company”) announced today that Lynn Stockwell has agreed to terms for a restructuring security agreement [...]
Vor Bio Announces $55.6 Million Private Placement
27/12/2024
Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33 ALLO in the first half of 2025 and updated clinical data from Phase 1/2a VBP101 trial of trem-cel in combination with Mylotarg in the second [...]
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update
27/12/2024
LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK); First commercial launch anticipated in H1 CY25 Received [...]
WEED Inc. President and CEO Releases Letter to Shareholders
27/12/2024
TUCSON, Ariz., Dec. 27, 2024 (GLOBE NEWSWIRE) -- via IBN – WEED Inc. (OTCQB: BUDZ ) , (“WEED,” “HEMP” or the “Company”), a global cannabis and hemp bioresearch company based in the U.S., shares the Company’s 2025 plans [...]
Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split
27/12/2024
STAMFORD, Conn., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) (the “ Company ”), today announced that a 1-for-12 reverse stock split of its outstanding shares of common stock and reduction in [...]
argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy
27/12/2024
VYVDURA ® now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP argenx's VYVGART ® and VYVDURA portfolio approved in Japan for three indications – first country globally with [...]
Park Ha Biological Technology Co., Ltd. Announces Pricing of $4.8 Million Initial Public Offering
27/12/2024
Wuxi, China, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Park Ha Biological Technology Co., Ltd. (the "Company"), a company focused on developing private skincare labels, direct skincare product sales, and franchise alliance [...]
Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives
26/12/2024
SAN DIEGO, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact [...]
Tevogen Bio to Host Panel Discussions “AI In Biopharma: Next Frontier of Medical Innovation” and “Pioneering the Economics of Health: Balancing Access and Outcomes” During J.P. Morgan Healthcare Conference
26/12/2024
The JPM Healthcare Conference is the largest and most informative health care investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators [...]
Recover Red Introduces Portable Red Light Therapy Solution: The Power Stack
26/12/2024
Portable, Travel-Friendly Device That Includes Everything You Need For On-The-Go Red Light Therapy. All Neatly Packed Into A Compact 12-Inch Travel Case PITTSBURGH, Dec. 26, 2024 (GLOBE NEWSWIRE) -- The widespread [...]
TOMI Environmental Solutions Announces Additional CES Installation at a Pharmaceutical Facility in the UK
26/12/2024
FREDERICK, Md., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, announced today another [...]
Vivos Inc.’s IsoPet® Division Achieves Exceptional Growth in 2024, Expanding Certified Veterinary Clinics Nationwide
26/12/2024
Richland, WA, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) is pleased to announce the significant achievements of its IsoPet ® Animal Cancer Division, setting new milestones in veterinary cancer care, and [...]
Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B
26/12/2024
– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing observed – – In the first 150 mg dose cohort, ABI-4334 showed strong antiviral activity with a mean reduction [...]
Optinose Announces 1-for-15 Reverse Stock Split
26/12/2024
YARDLEY, Pa., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Optinose, Inc. (NASDAQ: OPTN) , a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it will [...]

Pages